MedTrace Logo

Effect of Perampanel on Peritumoral Hyperexcitability in HGG

NCT04497142 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2024-08-05

Study results available
· View outcomes & findings →

Summary

The purpose of this research study is to learn more about seizures in people with primary brain tumors. It will evaluate whether an antiseizure medication decreases hyperexcitability activity around tumors and prevents seizures.

The procedure and study drug involved in this study are:

* Electrocorticography
* Perampanel (Fycompa)

Conditions

Interventions

DRUG

Perampanel

Tablet taken orally 1x daily.

DRUG

Standard of Care

Predetermined standard of care drug and dosing

Sponsors & Collaborators

Principal Investigators

  • Jong Woo Lee, MD, PhD · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-05
Primary Completion
2023-05-16
Completion
2023-05-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04497142 on ClinicalTrials.gov